Jiangsu Hengrui Pharmaceuticals leads $139B in biotech deals

by@Reuters

Summary

On October 16, 2026, it was reported that China's biotech sector is demonstrating significant advancements in deal-making as global pharmaceutical companies increasingly turn to Chinese innovators to enhance their development pipelines. Year-to-date agreements have exceeded $139 billion, surpassing last year's total, largely due to the improved negotiation tactics of Chinese drugmakers, who are now incorporating equity stakes, warrants, and bundled options into their contracts. For instance, Jiangsu Hengrui Pharmaceuticals recently licensed weight loss drugs to a US-based entity, securing almost $6 billion in upfront and milestone payments while also obtaining a 20% equity stake. This evolution in deal sophistication reflects a growing confidence among Chinese firms as they position themselves within the lucrative global markets for oncology, obesity, and autoimmune disease treatments.

Tokens

$600276.SS$AZN$GSK$NOVN$KLRA.O

Analysis

GSK: GSK is a global pharmaceutical company active in vaccines, specialty medicines and general pharmaceuticals. It acquired a small US firm that had licensed an asthma drug from a Chinese biotech, thereby gaining rights to the asset. GSK is among the international companies entering agreements with Chinese innovators to bolster their pipelines. Aiolos: Aiolos was a small US-based company that acquired rights to an asthma drug candidate from a Chinese biotech in a modest upfront deal. The firm was subsequently acquired by a major global pharmaceutical player, transferring the licensed asset. This transaction highlighted evolving deal dynamics between Chinese originators and US entities. AstraZeneca: AstraZeneca is a global pharmaceutical company with a broad pipeline in oncology, cardiovascular and respiratory diseases. It has participated in multiple outlicensing deals with Chinese biotechs for development and commercialization rights outside China. These partnerships help address pipeline needs through access to innovative candidates from Chinese researchers. Novo Nordisk: Novo Nordisk is a global pharmaceutical company specializing in diabetes and obesity treatments. It has entered into outlicensing agreements with Chinese biotechs covering metabolic and other therapeutic innovations. These deals support the company's efforts to expand its development portfolio through international partnerships. Kailera Therapeutics: Kailera Therapeutics is a US-based biotechnology company focused on metabolic therapies, originally formed as Hercules with backing from a major private equity firm. It licensed a portfolio of GLP-1 weight-loss candidates from a Chinese biotech under terms that included equity participation for the licensor. The company completed a New York listing and has pursued development of the in-licensed assets. Jiangsu Hengrui Pharmaceuticals: Jiangsu Hengrui Pharmaceuticals is a major Chinese pharmaceutical company engaged in drug discovery and development across therapeutic areas including oncology and respiratory conditions. It has shifted to more value-creating deal structures in recent outlicensing transactions, such as securing equity in a US partner alongside milestone payments for its GLP-1 assets. The company previously licensed an asthma candidate to a small US firm that was later acquired by a larger player. Pipeline Strategy: Global pharmaceutical companies are turning to Chinese innovators for promising candidates in high-demand areas such as oncology, obesity and autoimmune diseases to replenish development pipelines. Deal Sophistication: Chinese licensors are incorporating equity stakes, warrants and bundled options into agreements to capture greater long-term value beyond traditional upfront and milestone payments.

Categories

macro
View Original Tweet